Skip to main content

Select Drug Profiles

Renal-Cell Carcinoma, Oncology
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
Read More
Is Biomarker Testing in NSCLC Cost-Effective?
Caroline Helwick
Read More
Lung Cancer, Oncology
Non–Small-Cell Lung Cancer Testing Can Be Offered Routinely in Community Hospitals
Wayne Kuznar
Read More
Renal-Cell Carcinoma, Oncology
Quality of Life Drives Patient Preference for Metastatic RCC Drug
Wayne Kuznar
Read More
Lung Cancer, Oncology
Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
Read More
Breast Cancer, Oncology
Novel T-DM1 Prolongs Remission in Metastatic Breast Cancer: A New “Smart Bomb”
Audrey Andrews
Read More
Prostate Cancer
Enzalutamide Extends Survival, Improves QOL in Advanced Prostate Cancer
Wayne Kuznar
Read More
Patient Adherence Rises with Cost of Oral Cancer Drugs
Caroline Helwick
Read More
Practice Management
Curbing the Costly Trend: Exploring the Need for a Progressive Approach to the Management of Specialty Pharmaceuticals Under the Medical Benefit
Michael S. Jacobs, RPh, Kjel A. Johnson, PharmD, BcPS, FccP, FAMcP
Stakeholder Perspective
Managing Medical Benefit Drugs Under Specialty Pharmacy: The Next Critical Challenge for Managed Care
by James T. Kenney, RPh, MBA
Read More
Original Research
Anticoagulant Use for Prevention of Stroke in a Commercial Population with Atrial Fibrillation
Aarti A. Patel, PharmD, MBA, Barbara Lennert, RN, BSN, MAOM, Brian Macomson, PharmD, Winnie W. Nelson, PharmD, Gary M. Owens, MD, Samir H. Mody, PharmD, MBA, Jeff Schein, DrPH, MPH
Stakeholder Perspective
The Enormous Impact of Atrial Fibrillation and Stroke on Patients, Payers, and Society
by Jack E. Fincham, PhD, RPh
Read More
Page 200 of 244
Results 1991 - 2000 of 2434